Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—Olympus released its IXplore SpinSR10 imaging system, which aims to balance speed, resolution, and efficiency in a single, flexible platform. A high frame rate and 120 nm XY resolution enable researchers to observe the fine details and workings of internal cellular structures while offering the ability to switch between super-resolution, confocal, and wide-field imaging modes.
November 2017—Beckman Coulter Diagnostics received CE mark clearance for a high-sensitivity troponin assay that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.
November 2017—DiaSorin Molecular announced the U.S. introduction of the Simplexa C. difficile Direct Assay upon receiving clearance from the Food and Drug Administration.
November 2017—Natera announced that its Panorama noninvasive prenatal test is validated to screen twin pregnancies for zygosity and chromosomal abnormalities. Panorama can tell the difference between the mother’s and the baby’s DNA, enabling it to distinguish between each twin’s DNA.
November 2017—The CW3 Cell Washer, from Thermo Scientific, is an FDA-cleared, fully automated, high-performance cell washer designed to enable precise, thorough, reproducible, and rapid blood cell washing of up to 24 tubes in a three-minute run.
November 2017—Meridian Life Science launched its next-generation active human anti-mouse antibody (HAMA) blocker, TruBlock Ultra. It works over several assay types and blocks interference created by HAMA, rheumatoid factor, and heterophilic antibodies.
November 2017—Ortho Clinical Diagnostics received FDA approval for the Vitros Immunodiagnostic Products HBeAg Assay and the Vitros Anti-HBe Assay for use on the Vitros 3600 Immunodiagnostic System and 5600 Integrated System.
November 2017—Rosetta Genomics entered into a definitive agreement in early September to sell all of its ownership interest in PersonalizeDx to Pragmin Prognosis.
November 2017—Agilent Technologies announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the FDA for use as an aid in identifying gastric or gastroesophageal junction adenocarcinoma patients for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck.
November 2017—Sciex Diagnostics showcased its Sciex Topaz System at the 4th Annual European Congress and Exhibition of the Association for Mass Spectrometry: Applications to the Clinical Lab in Salzburg, Austria, in September.
